Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

Solid Biosciences Inc. (NASDAQ:SLDB) said COO Alvaro Amorrortu and CMO Chief Jorge Quiroz will step down as the company restructures, reducing its workforce by about one third, to extend its runway. Amorrortu and Quiroz will continue as advisers. Solid is seeking to establish a development path for its lead gene therapy SGT-001, which FDA placed on a second clinical hold in November. It is curtailing development of other programs and reducing its workforce by about one third (see “Gene Therapy Holding Pattern”).

Rare genetic disease company Abeona Therapeutics Inc. (NASDAQ:ABEO) disclosed in a regulatory filing that co-founder, president and CSO Tim Miller is resigning on Friday. ...